ORMOND BEACH, Fla., September 23, 2026 — Germfree, a full-lifecycle engineering and manufacturing partner for mission-critical environments across life sciences, healthcare and biocontainment, today announced the appointment of Adam Simon as Chief Financial Officer and Geoffrey Schwartz as Chief Commercial Officer, alongside a refreshed brand identity and redesigned Germfree.com. Together, Simon and Schwartz add two capabilities central to Germfree’s growth: the financial and operating architecture required to scale a more sophisticated enterprise, and the commercial leadership required to stay closely connected to customers and markets.

The moves reflect a broader evolution underway at Germfree as the company builds for its next era of growth. Simon will focus on building the financial and operating infrastructure required for the company’s next stage — moving Germfree toward greater enterprise-level discipline and creating a scalable platform capable of supporting both organic growth and, over time, a broader portfolio of complementary businesses. Schwartz will help deepen Germfree’s customer and market strategy as the company expands its role as a strategic partner across life sciences and healthcare.

Across advanced therapies, biomanufacturing, hospital and compounding pharmacy, and high-containment applications, customers are navigating increasingly complex requirements and seeking partners capable of taking greater accountability across critical infrastructure, equipment and lifecycle support.

Germfree’s refreshed tagline, Made for Mission Critical, puts language around the role the company has played since 1962 designing, building and supporting environments where safety, reliability and execution matter.

As part of that evolution, Germfree has strengthened its executive leadership team with two leaders whose experience directly supports the company’s next phase.

Simon joins Germfree as Chief Financial Officer after serving as Senior Vice President of Finance at regenerative medicine company StimLabs, following 15 years serving private equity portfolio and family owned businesses at PwC. He brings a combination of financial rigor, operating experience and life sciences industry knowledge.

“Germfree has significant opportunity ahead and realizing that opportunity requires us to build for the company we intend to become, not simply the company we are today,” said Simon. “My focus is on creating the financial discipline, operating infrastructure and visibility needed to scale the enterprise responsibly and support its continued evolution.”

Schwartz joins Germfree as Chief Commercial Officer with nearly three decades of life sciences leadership experience. Most recently, he served as CEO and General Manager of Mirus Bio and previously as the company’s Chief Commercial Officer, including through its acquisition by MilliporeSigma.

“Our customers are solving increasingly complex problems and need partners who understand how facilities, equipment, process and lifecycle support come together,” said Schwartz. “Germfree has the opportunity to bring those capabilities together in a highly differentiated way, and I am excited to help build that future.”